AIM: To determine the incidence of and the risk factors for cytomegalovirus (CMV) symptomatic infection and end-organ disease after autologous stem cell transplantation (ASCT). METHODS: A total of 327 consecutive non CD34(+) selected autografts performed from the Hematology and Stem Cell Transplantation Unit of Regina Elena National Cancer Institute of Rome (Italy) in the period comprised between January 2003 to January 2015, were reviewed. Over the 327 autografts, 201 were performed in patients with multiple myeloma, whereas the remaining 126 in patients affected by non-Hodgkin's lymphoma and Hodgkin's lymphoma. The patients who underwent an ASCT for an acute leukemia (n = 20) in the same period were excluded from this analysis. CMV DNA load in the blood has been determined by polymerase-chain reaction in the case of a clinical suspicion of reactivation, therefore, no routine monitoring strategy was adopted. In the presence of signs and symptoms of CMV reactivation an antiviral treatment was performed. RESULTS: Overall, 36 patients (11%) required a specific antiviral treatment for a symptomatic CMV reactivation (n = 32) or an end-organ disease (n = 4). We observed 20 and 16 cases of CMV reactivation among lymphoma (16%) and myeloma patients (8%), respectively. Among cases of end-organ disease, 3 were diagnosed as interstitial pneumonia and one remaining case as hemorrhagic enteritis. All cases of CMV reactivation were observed in IgG seropositive patients, with no documented cases of primary CMV infection. All patients were treated with a specific antiviral therapy, with a global rate of hospitalization of 55%; four patients received intravenous immunoglobulins. Transplant-related mortality was significantly higher in patients who experienced a CMV reactivation (8.4% ± 4.7% vs 1.7% ± 0.8%; P = 0.047). In univariate analysis, a pre-transplant HBcIgG seropositivity, a diagnosis of T-cell non-Hodgkin's lymphoma and higher median age at transplant were significantly associated with the risk of developing a clinically relevant CMV infection requiring specific antiviral therapy (P < 0.001, P = 0.042 and P = 0.004, respectively). In multivariate analysis, only a pre-transplant HBcIgG seropositivity (OR = 8.928, 95%CI: 1.991-33.321; P = 0.023) and a diagnosis of T-cell non-Hodgkin's lymphoma (OR = 4.739, 95%CI: 1.511-11.112; P = 0.042) proved to be independent predictors of a post-transplant clinically relevant CMV reactivation. CONCLUSION: A symptomatic CMV infection can occur in about 11% of adult patients with lymphoma or myeloma undergoing ASCT. A pre-transplant HBcIgG seropositivity and a diagnosis of T-cell non-Hodgkin's lymphoma should be considered as independent predictor factors of CMV reactivation.
AIM: To determine the incidence of and the risk factors for cytomegalovirus (CMV) symptomatic infection and end-organ disease after autologous stem cell transplantation (ASCT). METHODS: A total of 327 consecutive non CD34(+) selected autografts performed from the Hematology and Stem Cell Transplantation Unit of Regina Elena National Cancer Institute of Rome (Italy) in the period comprised between January 2003 to January 2015, were reviewed. Over the 327 autografts, 201 were performed in patients with multiple myeloma, whereas the remaining 126 in patients affected by non-Hodgkin's lymphoma and Hodgkin's lymphoma. The patients who underwent an ASCT for an acute leukemia (n = 20) in the same period were excluded from this analysis. CMV DNA load in the blood has been determined by polymerase-chain reaction in the case of a clinical suspicion of reactivation, therefore, no routine monitoring strategy was adopted. In the presence of signs and symptoms of CMV reactivation an antiviral treatment was performed. RESULTS: Overall, 36 patients (11%) required a specific antiviral treatment for a symptomatic CMV reactivation (n = 32) or an end-organ disease (n = 4). We observed 20 and 16 cases of CMV reactivation among lymphoma (16%) and myelomapatients (8%), respectively. Among cases of end-organ disease, 3 were diagnosed as interstitial pneumonia and one remaining case as hemorrhagic enteritis. All cases of CMV reactivation were observed in IgG seropositive patients, with no documented cases of primary CMV infection. All patients were treated with a specific antiviral therapy, with a global rate of hospitalization of 55%; four patients received intravenous immunoglobulins. Transplant-related mortality was significantly higher in patients who experienced a CMV reactivation (8.4% ± 4.7% vs 1.7% ± 0.8%; P = 0.047). In univariate analysis, a pre-transplant HBcIgG seropositivity, a diagnosis of T-cell non-Hodgkin's lymphoma and higher median age at transplant were significantly associated with the risk of developing a clinically relevant CMV infection requiring specific antiviral therapy (P < 0.001, P = 0.042 and P = 0.004, respectively). In multivariate analysis, only a pre-transplant HBcIgG seropositivity (OR = 8.928, 95%CI: 1.991-33.321; P = 0.023) and a diagnosis of T-cell non-Hodgkin's lymphoma (OR = 4.739, 95%CI: 1.511-11.112; P = 0.042) proved to be independent predictors of a post-transplant clinically relevant CMV reactivation. CONCLUSION: A symptomatic CMV infection can occur in about 11% of adult patients with lymphoma or myeloma undergoing ASCT. A pre-transplant HBcIgG seropositivity and a diagnosis of T-cell non-Hodgkin's lymphoma should be considered as independent predictor factors of CMV reactivation.
Authors: L A Holmberg; M Boeckh; H Hooper; W Leisenring; S Rowley; S Heimfeld; O Press; D G Maloney; P McSweeney; L Corey; R T Maziarz; F R Appelbaum; W Bensinger Journal: Blood Date: 1999-12-15 Impact factor: 22.113
Authors: Ashley P Ng; Leon Worth; Luke Chen; John F Seymour; H Miles Prince; Monica Slavin; Karin Thursky Journal: Haematologica Date: 2005-12 Impact factor: 9.941
Authors: H Hebart; A Schröder; J Löffler; T Klingebiel; H Martin; B Wassmann; F Gerneth; H Rabenau; G Jahn; L Kanz; C A Müller; H Einsele Journal: J Infect Dis Date: 1997-06 Impact factor: 5.226
Authors: E S Daar; H Lynn; S Donfield; E Gomperts; S J O'Brien; M W Hilgartner; W K Hoots; D Chernoff; S Arkin; W Y Wong; C A Winkler Journal: J Infect Dis Date: 2001-01-12 Impact factor: 5.226
Authors: Evren Ozdemir; Lisa S St John; Geraldine Gillespie; Sarah Rowland-Jones; Richard E Champlin; Jeffrey J Molldrem; Krishna V Komanduri Journal: Blood Date: 2002-07-05 Impact factor: 22.113
Authors: Michael Scordo; Sejal M Morjaria; Eric R Littmann; Ankush Bhatia; Helen H Chung; Molly Maloy; Lisa M DeAngelis; Sergio A Giralt; Ying Taur; Craig S Sauter Journal: Biol Blood Marrow Transplant Date: 2018-04-18 Impact factor: 5.742
Authors: Ane Orrantia; Iñigo Terrén; Gabirel Astarloa-Pando; Carmen González; Alasne Uranga; Juan J Mateos-Mazón; Juan C García-Ruiz; Marta Riñón; Mercedes Rey; Silvia Pérez-Fernandez; Olatz Zenarruzabeitia; Francisco Borrego Journal: Front Immunol Date: 2021-10-05 Impact factor: 7.561
Authors: Marko Janković; Aleksandra Knežević; Milena Todorović; Irena Đunić; Biljana Mihaljević; Ivan Soldatović; Jelena Protić; Nevenka Miković; Vera Stoiljković; Tanja Jovanović Journal: Virol J Date: 2022-09-29 Impact factor: 5.913